Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from AdAlta Ltd. ( (AU:1AD) ) is now available.
AdAlta has formally launched its “East-to-West” cellular immunotherapy strategy through a co-development deal with Shanghai Cell Therapy Group for BZDS1901, a first-in-class mesothelin-targeting CAR-T therapy for mesothelioma and other solid tumours. Early Chinese clinical data in heavily pre-treated mesothelioma patients show tumour responses in up to half of participants and complete tumour clearance in about one-fifth, including one patient still disease-free 22 months post-treatment, highlighting significant potential in a market with limited options and multibillion-dollar revenue prospects.
To support global development and partnering, AdAlta has initiated technology transfer of BZDS1901 manufacturing to Australia via a work order with Cell Therapies and signed an MoU with Cell Therapies and Oribiotech to introduce an automated cell therapy production platform in Australia and the Asia-Pacific region. This manufacturing push, combined with modest new funding from a private placement and R&D tax refunds, is intended to improve scalability, lower development costs and enhance the licensing value of BZDS1901 as it advances toward future Australian Phase 1 trials.
More about AdAlta Ltd.
AdAlta Limited is an Australian biotechnology company developing next-generation cell and protein therapeutics, with a growing focus on cellular immunotherapies. Leveraging Australian manufacturing and clinical expertise, it aims to adapt leading Asian cell therapy innovations, such as CAR-T treatments, for Western-regulated markets in oncology.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$10.2M
For detailed information about 1AD stock, go to TipRanks’ Stock Analysis page.